Status:

COMPLETED

Dietary Intervention and Gastrointestinal Function in Patients With Parkinson's Disease

Lead Sponsor:

University of Florida

Conditions:

Parkinson Disease

Eligibility:

All Genders

21-85 years

Phase:

NA

Brief Summary

In this prospective, intervention study, participants with diagnosed Parkinson's disease will be instructed to follow a Mediterranean diet for five weeks. Gut permeability will be assessed using food-...

Eligibility Criteria

Inclusion

  • Physician-diagnosed Parkinson's disease aged 21-85 years
  • Hoehn \& Yahr stage \<3
  • Currently living in the same household with a healthy spouse/partner who meets study eligibility criteria and is willing to participate
  • Willing and able to complete informed consent in English
  • Willing to complete daily and weekly questionnaires and 6 dietary recalls over approximately 7 weeks
  • Willing to avoid beer, wine, and cocktails on the day before and the day of the sugar probe tests.
  • Willing to provide urine and stool samples during the study collection periods.
  • Willing and able to fast (no food or drink, except water or tea) for a prolonged period of time during study urine collections.
  • Willing to maintain usual diet through the pre-baseline period
  • Willing to make dietary changes to follow a Mediterranean dietary pattern during the intervention period.
  • Willing to discontinue taking prebiotic, fiber, probiotic, herbal, or high-dose vitamin or mineral supplements that may impact inflammation during the pre-baseline period and throughout the study protocol.
  • Willing to limit use of oral laxative medication to an "as-needed basis" (i.e. \<3 times per week) during the full length of the study
  • Willing to avoid high intensity exercises two days prior to and the day of the permeability tests. These tests will be done on two occasions.
  • Willing to provide a social security number to receive study payment.

Exclusion

  • Does not meet above criteria
  • Atypical or secondary Parkinsonism
  • History of deep brain stimulation
  • Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening.
  • Daily use of anticholinergics or prokinetic agents
  • Use of enemas or suppositories to alleviate constipation
  • Use of another investigational product within 3 months of the screening visit.
  • Antibiotic use within 2 months from the day of stool collection
  • Good adherence to the Mediterranean diet during the pre-baseline period (score \>6) based on the 14-item Mediterranean Diet Assessment Tool
  • Physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, cancer, peptic ulcer disease, Celiac disease, short bowel disease, ileostomy, colostomy) other than gastroesophageal reflux or diverticular disease

Key Trial Info

Start Date :

April 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 3 2021

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT03851861

Start Date

April 15 2019

End Date

May 3 2021

Last Update

May 4 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Florida

Gainesville, Florida, United States, 32611